Modified Release Ibuprofen Dosage Form with Segmented Release Phases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ibuprofen formulations, especially immediate release forms, provide rapid but short-lived therapeutic effects, necessitating frequent dosing and are difficult to manufacture due to issues like friability and sticking during tableting, and lack sustained release profiles to maintain effective blood levels over extended periods.
Innovation Solution
A solid dosage form combining hydrophilic polymers like HPMC with ibuprofen, dissolution additives, and formulation additives to achieve an initial burst followed by sustained release, maintaining therapeutic blood levels for at least 8 hours, using a dry blend that eliminates the need for pre-granulation and improves manufacturability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release ibuprofen dosage forms are used, then rapid onset of therapeutic action is achieved, but therapeutic levels are not maintained over extended periods requiring repeated dosing
Solution Approach 1:
The ibuprofen dosage form is segmented into two distinct release phases: an immediate release component providing rapid onset (first 2 hours) and a sustained release component maintaining therapeutic levels over extended periods (8-12 hours). This segmentation allows simultaneous achievement of rapid onset and prolonged duration by combining different release mechanisms within a single dosage form.
Solution Approach 2:
The patent merges immediate release and sustained release mechanisms into a single unified dosage form. The formulation combines rapidly dissolving ibuprofen particles with a sustained release matrix, allowing both release profiles to operate simultaneously in one tablet, thereby eliminating the need for separate immediate and extended release products.
2Ease of manufacture
If ibuprofen is directly compressed into tablets, then manufacturing process is simplified, but tablets exhibit sticking, friability, and splitting issues
Solution Approach 1:
A hydrophilic polymer matrix acts as an intermediary carrier for the ibuprofen particles. This polymer matrix serves as a binding agent that prevents direct compression of ibuprofen crystals, eliminating sticking and friability issues while maintaining manufacturing simplicity. The polymer acts as a mediating substance that enables direct compression without compromising tablet integrity.
Solution Approach 2:
The dosage form uses a composite material system combining hydrophilic polymer with ibuprofen particles. This composite structure provides both the mechanical integrity needed for reliable tablet formation and the controlled release properties required for therapeutic effectiveness, resolving the contradiction between manufacturing ease and product reliability.
3Duration of action of moving object
If extended release formulations are used, then sustained therapeutic levels are maintained, but initial burst of drug release is delayed
Solution Approach 1:
The release profile is segmented into two distinct phases: an immediate release phase providing rapid initial burst (achieving therapeutic levels within 2 hours) and a sustained release phase maintaining therapeutic levels over 8-12 hours. This segmentation ensures both rapid onset and prolonged duration are achieved simultaneously in a single dosage form.
Solution Approach 2:
Different regions of the dosage form have different release characteristics: the immediate release component provides rapid initial drug release, while the sustained release matrix provides prolonged therapeutic level maintenance. This local differentiation of release properties allows the single dosage form to simultaneously achieve both rapid onset and extended duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves an initial rapid release of ibuprofen within 2 hours, followed by a sustained release maintaining levels above 6.4 μg/ml for 8-12 hours, reducing the need for frequent dosing and improving manufacturing ease by avoiding sticking and friability issues.
Implementation Method 1
a solid dosage form for oral administration comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release
Implementation Method 2
a dissolution additive dispersed in the polymer in an amount in the range of 10% to 35% by weight of the ibuprofen
Data Source
AI summary
The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose.